Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.

Gherardin NA, Loh L, Admojo L, Davenport AJ, Richardson K, Rogers A, Darcy PK, Jenkins MR, Prince HM, Harrison SJ, Quach H, Fairlie DP, Kedzierska K, McCluskey J, Uldrich AP, Neeson PJ, Ritchie DS, Godfrey DI.

Sci Rep. 2018 Mar 7;8(1):4159. doi: 10.1038/s41598-018-22130-1.


Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.

Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, Darcy PK, Neeson PJ, Jenkins MR.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2068-E2076. doi: 10.1073/pnas.1716266115. Epub 2018 Feb 12.


How Robust is the Influence of Causal Explanation on Clinical Judgments? Assessments in Structured Clinical Interviews.

Jenkins MR, Kim NS.

J Psychol. 2018 Feb 17;152(2):96-109. doi: 10.1080/00223980.2017.1407741. Epub 2018 Jan 11.


PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, Jenkins MR, Rogers AJ, Neeson PJ, Korman AJ, Robbins MD, Graziano RF.

Blood Adv. 2017 May 8;1(12):753-765. doi: 10.1182/bloodadvances.2017004382. eCollection 2017 May 9.


Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice.

Trivedi PM, Graham KL, Scott NA, Jenkins MR, Majaw S, Sutherland RM, Fynch S, Lew AM, Burns CJ, Krishnamurthy B, Brodnicki TC, Mannering SI, Kay TW, Thomas HE.

Diabetes. 2017 Jun;66(6):1650-1660. doi: 10.2337/db16-1250. Epub 2017 Mar 14.


HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.

Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, Trapani JA, Smyth MJ, Darcy PK, Atadja PW, Henderson MA, Johnstone RW, Haynes NM.

Cancer Res. 2017 May 15;77(10):2594-2606. doi: 10.1158/0008-5472.CAN-16-2247. Epub 2017 Mar 1.


Sex and gender in medical education: a national student survey.

Jenkins MR, Herrmann A, Tashjian A, Ramineni T, Ramakrishnan R, Raef D, Rokas T, Shatzer J.

Biol Sex Differ. 2016 Oct 14;7(Suppl 1):45. eCollection 2016.


High Cardiorespiratory Fitness Is Associated with Reduced Risk of Low Bone Density in Postmenopausal Women.

DeFina LF, Leonard D, Willis BL, Barlow CE, Finley CE, Jenkins MR, Pence BC, Zhang Y, Chyu MC, Lewiecki EM, Shen CL.

J Womens Health (Larchmt). 2016 Oct;25(10):1073-1080. Epub 2016 Jan 28.


Improving Medical Education Using a Sex- and Gender-Based Medicine Lens.

Rojek MK, Jenkins MR.

J Womens Health (Larchmt). 2016 Oct;25(10):985-989. Epub 2016 Jul 22.


21st Century Women's Health: Refining With Precision.

Jenkins MR, Miller VM.

Mayo Clin Proc. 2016 Jun;91(6):695-700. doi: 10.1016/j.mayocp.2016.03.017. Epub 2016 May 5. No abstract available.


Serglycin determines secretory granule repertoire and regulates natural killer cell and cytotoxic T lymphocyte cytotoxicity.

Sutton VR, Brennan AJ, Ellis S, Danne J, Thia K, Jenkins MR, Voskoboinik I, Pejler G, Johnstone RW, Andrews DM, Trapani JA.

FEBS J. 2016 Mar;283(5):947-61. doi: 10.1111/febs.13649. Epub 2016 Jan 22.


CAR-T cells are serial killers.

Davenport AJ, Jenkins MR, Ritchie DS, Prince HM, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ.

Oncoimmunology. 2015 Jun 1;4(12):e1053684. eCollection 2015 Dec.


Development of a PubMed Based Search Tool for Identifying Sex and Gender Specific Health Literature.

Song MM, Simonsen CK, Wilson JD, Jenkins MR.

J Womens Health (Larchmt). 2016 Feb;25(2):181-7. doi: 10.1089/jwh.2015.5217. Epub 2015 Nov 10.


Women's health 2015: an update for the internist.

Kransdorf LN, McNeil MA, Files JA, Jenkins MR.

Cleve Clin J Med. 2015 Nov;82(11):759-64. doi: 10.3949/ccjm.82a.15096. Review.


Perforin-dependent cytotoxicity: 'Kiss of death' or prolonged embrace with darker elocation-idnseque11es?

Trapani JA, Voskoboinik I, Jenkins MR.

Oncoimmunology. 2015 Apr 14;4(9):e1036215. eCollection 2015 Sep.


Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis.

Colombo M, Mirandola L, Reidy A, Suvorava N, Konala V, Chiaramonte R, Grizzi F, Rahman RL, Jenkins MR, Nugyen DD, Dalhbeck S, Cobos E, Figueroa JA, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):188-99. doi: 10.3109/08830185.2015.1027629. Review.


Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.

Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Review.


Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium.

Mirandola L, Wade R, Verma R, Pena C, Hosiriluck N, Figueroa JA, Cobos E, Jenkins MR, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):134-42. doi: 10.3109/08830185.2015.1018417. Review.


Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.

Mirandola L, Figueroa JA, Phan TT, Grizzi F, Kim M, Rahman RL, Jenkins MR, Cobos E, Jumper C, Alalawi R, Chiriva-Internati M.

Oncotarget. 2015 Feb 20;6(5):2812-26.


Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time.

Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, Voskoboinik I, Trapani JA.

J Exp Med. 2015 Mar 9;212(3):307-17. doi: 10.1084/jem.20140964. Epub 2015 Mar 2.


CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells.

Davenport AJ, Jenkins MR, Cross RS, Yong CS, Prince HM, Ritchie DS, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ.

Cancer Immunol Res. 2015 May;3(5):483-94. doi: 10.1158/2326-6066.CIR-15-0048. Epub 2015 Feb 24.


Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer.

Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M.

Gynecol Oncol. 2014 Dec;135(3):573-9. doi: 10.1016/j.ygyno.2014.09.021. Epub 2014 Oct 6.


Guidelines for managing high blood pressure.

Klein WS, Merz CN, Jenkins MR.

JAMA. 2014 Jul 16;312(3):294-5. doi: 10.1001/jama.2014.6593. No abstract available.


Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?

Mirandola L, Nguyen DD, Rahman RL, Grizzi F, Yuefei Y, Figueroa JA, Jenkins MR, Cobos E, Chiriva-Internati M.

Int Rev Immunol. 2014 Oct;33(5):417-27. doi: 10.3109/08830185.2014.911855. Epub 2014 May 6. Review.


Distinct structural and catalytic roles for Zap70 in formation of the immunological synapse in CTL.

Jenkins MR, Stinchcombe JC, Au-Yeung BB, Asano Y, Ritter AT, Weiss A, Griffiths GM.

Elife. 2014 Mar 4;3:e01310. doi: 10.7554/eLife.01310.


Meclizine enhancement of sensorimotor gating in healthy male subjects with high startle responses and low prepulse inhibition.

Larrauri JA, Kelley LD, Jenkins MR, Westman EC, Schmajuk NA, Rosenthal MZ, Levin ED.

Neuropsychopharmacology. 2014 Feb;39(3):651-9. doi: 10.1038/npp.2013.248. Epub 2013 Sep 18.


Rapid and unidirectional perforin pore delivery at the cytotoxic immune synapse.

Lopez JA, Jenkins MR, Rudd-Schmidt JA, Brennan AJ, Danne JC, Mannering SI, Trapani JA, Voskoboinik I.

J Immunol. 2013 Sep 1;191(5):2328-34. doi: 10.4049/jimmunol.1301205. Epub 2013 Jul 24.


Advancing sex and gender competency in medicine: sex & gender women's health collaborative.

McGregor AJ, Templeton K, Kleinman MR, Jenkins MR.

Biol Sex Differ. 2013 Jun 1;4(1):11. doi: 10.1186/2042-6410-4-11.


Embedding concepts of sex and gender health differences into medical curricula.

Miller VM, Rice M, Schiebinger L, Jenkins MR, Werbinski J, Núñez A, Wood S, Viggiano TR, Shuster LT.

J Womens Health (Larchmt). 2013 Mar;22(3):194-202. doi: 10.1089/jwh.2012.4193. Epub 2013 Feb 15.


Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack.

Lopez JA, Susanto O, Jenkins MR, Lukoyanova N, Sutton VR, Law RH, Johnston A, Bird CH, Bird PI, Whisstock JC, Trapani JA, Saibil HR, Voskoboinik I.

Blood. 2013 Apr 4;121(14):2659-68. doi: 10.1182/blood-2012-07-446146. Epub 2013 Feb 1.


Fruits and dietary phytochemicals in bone protection.

Shen CL, von Bergen V, Chyu MC, Jenkins MR, Mo H, Chen CH, Kwun IS.

Nutr Res. 2012 Dec;32(12):897-910. doi: 10.1016/j.nutres.2012.09.018. Epub 2012 Oct 30. Review.


Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.

Schutt C, Bumm K, Mirandola L, Bernardini G, Cunha N, Tijani L, Nguyen D, Cordero J, Jenkins MR, Cobos E, Kast WM, Chiriva-Internati M.

Int Rev Immunol. 2012 Feb;31(1):22-42. doi: 10.3109/08830185.2011.637253. Review.


Application of vitamin D and derivatives in hematological malignancies.

Kim M, Mirandola L, Pandey A, Nguyen DD, Jenkins MR, Turcel M, Cobos E, Chiriva-Internati M.

Cancer Lett. 2012 Jun 1;319(1):8-22. doi: 10.1016/j.canlet.2011.10.026. Epub 2011 Dec 19. Review.


Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4.

Mirandola L, Yu Y, Jenkins MR, Chiaramonte R, Cobos E, John CM, Chiriva-Internati M.

BMC Cancer. 2011 Sep 16;11:394. doi: 10.1186/1471-2407-11-394.


Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.

Mirandola L, Yu Y, Chui K, Jenkins MR, Cobos E, John CM, Chiriva-Internati M.

PLoS One. 2011;6(7):e21811. doi: 10.1371/journal.pone.0021811. Epub 2011 Jul 13.


Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy.

Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E.

J Immunother. 2011 Jul-Aug;34(6):490-9. doi: 10.1097/CJI.0b013e31821ca76f.


Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.

Mirandola L, J Cannon M, Cobos E, Bernardini G, Jenkins MR, Kast WM, Chiriva-Internati M.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):127-37. doi: 10.3109/08830185.2011.572504. Review.


Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.

Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):71-86. doi: 10.3109/08830185.2011.561507. Review.


Centrosome docking at the immunological synapse is controlled by Lck signaling.

Tsun A, Qureshi I, Stinchcombe JC, Jenkins MR, de la Roche M, Kleczkowska J, Zamoyska R, Griffiths GM.

J Cell Biol. 2011 Feb 21;192(4):663-74. doi: 10.1083/jcb.201008140.


Nanotechnology and human health: risks and benefits.

Cattaneo AG, Gornati R, Sabbioni E, Chiriva-Internati M, Cobos E, Jenkins MR, Bernardini G.

J Appl Toxicol. 2010 Nov;30(8):730-44. doi: 10.1002/jat.1609. Review.


Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM.

PLoS One. 2010 May 12;5(5):e10471. doi: 10.1371/journal.pone.0010471.


The synapse and cytolytic machinery of cytotoxic T cells.

Jenkins MR, Griffiths GM.

Curr Opin Immunol. 2010 Jun;22(3):308-13. doi: 10.1016/j.coi.2010.02.008. Epub 2010 Mar 11. Review.


The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse.

Jenkins MR, Tsun A, Stinchcombe JC, Griffiths GM.

Immunity. 2009 Oct 16;31(4):621-31. doi: 10.1016/j.immuni.2009.08.024.


Visualizing CTL activity for different CD8+ effector T cells supports the idea that lower TCR/epitope avidity may be advantageous for target cell killing.

Jenkins MR, La Gruta NL, Doherty PC, Trapani JA, Turner SJ, Waterhouse NJ.

Cell Death Differ. 2009 Apr;16(4):537-42. doi: 10.1038/cdd.2008.176. Epub 2009 Jan 9.


Granzyme K expressing cytotoxic T lymphocytes protects against influenza virus in granzyme AB-/- mice.

Jenkins MR, Trapani JA, Doherty PC, Turner SJ.

Viral Immunol. 2008 Sep;21(3):341-6. doi: 10.1089/vim.2008.0036.


Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.

Chiriva-Internati M, Weidanz JA, Yu Y, Frezza EE, Jenkins MR, Kennedy RC, Cobos E, Kast WM.

J Immunother. 2008 Oct;31(8):693-703. doi: 10.1097/CJI.0b013e31818283d5.


Cell cycle-related acquisition of cytotoxic mediators defines the progressive differentiation to effector status for virus-specific CD8+ T cells.

Jenkins MR, Mintern J, La Gruta NL, Kedzierska K, Doherty PC, Turner SJ.

J Immunol. 2008 Sep 15;181(6):3818-22.


Update on nonhormonal approaches to menopausal management.

Jenkins MR, Sikon AL.

Cleve Clin J Med. 2008 May;75 Suppl 4:S17-24. Review.


Putting the latest data into practice: case studies and clinical considerations in menopausal management.

McKenzie M, Sikon AL, Thacker HL, Gass M, Hodis HN, Jenkins MR.

Cleve Clin J Med. 2008 May;75 Suppl 4:S25-33. No abstract available.


The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma.

Chiriva-Internati M, Ferrari R, Prabhakar M, Yu Y, Baggoni L, Moreno J, Gagliano N, Portinaro N, Jenkins MR, Frezza EE, Hardwicke F, D'Cunha N, Kast W, Cobos E.

J Transl Med. 2008 Apr 2;6:15. doi: 10.1186/1479-5876-6-15.

Supplemental Content

Loading ...
Support Center